Whole-body FDG-PET imaging in the management of patients with cancer
- 1 January 2002
- journal article
- review article
- Published by Elsevier BV in Seminars in Nuclear Medicine
- Vol. 32 (1), 35-46
- https://doi.org/10.1053/snuc.2002.29272
Abstract
No abstract availableThis publication has 112 references indexed in Scilit:
- Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)Cancer Biotherapy & Radiopharmaceuticals, 2001
- PET Scanning in Malignancy: Infant, Adolescent or Mature Citizen?Annals of Surgery, 2001
- Whole-Body FDG Positron Emission Tomographic Imaging for Staging Esophageal CancerClinical Nuclear Medicine, 2000
- Positron Emission Tomography With Fluorodeoxyglucose for Suspected Head and Neck Tumor Recurrence in the Symptomatic PatientThe Laryngoscope, 2000
- Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose for the differentiation of chronic pancreatitis and pancreatic cancerBritish Journal of Surgery, 1999
- Liver Resection for Metastatic Colorectal Cancer: Assessing the Risk of Occult Irresectable DiseaseJournal of the American College of Surgeons, 1999
- Staging of the Axilla in Breast CancerAnnals of Surgery, 1998
- Assessment of Axillary Lymph Node Involvement in Breast Cancer Patients With Positron Emission Tomography Using Radiolabeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucoseJNCI Journal of the National Cancer Institute, 1996
- Positron emission tomography in the detection and management of metastatic melanomaMelanoma Research, 1996
- Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-GlucoseJournal of Computer Assisted Tomography, 1993